MedPath

To compare the efficacy Of raktavasechana ( jalaukavacharana ) and manjistha lepa On facial blemishes.

Phase 2
Conditions
Health Condition 1: L811- ChloasmaHealth Condition 2: L599- Disorder of the skin and subcutaneous tissue related to radiation, unspecified
Registration Number
CTRI/2023/08/056716
Lead Sponsor
Shri Krishna Government Ayurvedic College and Hospital kurukshetra
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients presenting with classical signs and symptoms of vyanga were selected.

2. Age groups between 16-60 years were selected.

3. Both the sex.

4. Chronicity less than 2 years

5. Patients yogya for Lepa and raktavsechana.

6. Patient willing to sign the consent form.

7. Patient not taking any other medicine for Hyperpigmentation.

8. Patient with classical symptoms of vyanga.

Exclusion Criteria

1. Patients ayogya for Lepa and raktavsechana.

2. Malignant melanoma

3. Acne Vulgaris,riehls melanosis, Poikiloderma of civtte.

4. Patients with other Systemic disorders.

5. Severe Anemia, pregnancy, any kind of noted drug allergy

6. Patient below the age 16 year and above 60 years.

7. Patient with Leprosy, Tuberculosis and Paralysis.

8. Hyperpigmentation caused due to any systemic disease such as Addisons disease,

Cushing syndrome and Systemic lupus erythematous.

9. Patient with uncontrolled Hypertension/Cardiac problem/Diabetes Mellitus and any

systematic disorder.

10. Hyperpigmentation since birth like Nevus of Ota and those caused by tumors such

as malignant melanoma.

11. Exogenous ochronosis is a cutaneous disorder characterized by blue-black

pigmentation resulting as a complication of long term application of skin

lightening creams containing hydroquinone.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The outcome will be assessed on basis of improvement in MASI SCORE.Timepoint: At the baseline 30th & 60th day.
Secondary Outcome Measures
NameTimeMethod
The outcome will be assessed on basis of improvement in sign & lesion color through color grading scale.Timepoint: at the baseline 30th & 60th day.
© Copyright 2025. All Rights Reserved by MedPath